What is MBX Biosciences, Inc. Common Stock (MBX) stock price today?

MBX Biosciences, Inc. Common Stock (MBX) currently trades at $30.22 per share. The stock has a market capitalization of $1.38B and a P/E ratio of —x.

Is MBX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, MBX Biosciences, Inc. Common Stock has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 13.14.

Is MBX Biosciences, Inc. Common Stock financially healthy?

MBX Biosciences, Inc. Common Stock's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 13.14 places it in the safe zone.

MBX

MBX Biosciences, Inc. Common Stock

NASDAQ: MBX · HEALTHCARE · BIOTECHNOLOGY

$30.22

+5.63% today

Updated 2026-04-30

Market cap

$1.38B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.38

Dividend yield

—

52W range

$9 – $45

Volume

0.5M

Market cap

$1.38B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.38

Dividend yield

—

52W range

$9 – $45

Volume

0.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.3

Quality

B+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

13.1

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

$62.55

+106.98%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy9 Buy0 Hold1 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 13.14 — safe zone

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-19.09M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-26.14M	$-32.56M	$-61.92M	$-86.97M	$-22.06M
EPS	—	—	—	—	$-2.38
Free cash flow	$-23.56M	$-32.11M	$-55.55M	$-81.88M	$-19.09M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MBX	$1.38B	26	4.3	3.0	5.0	7.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

MBX Biosciences, Inc. Common Stock trades at $30.22. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 13.14, it sits in the safe zone.

Frequently asked questions

What is MBX Biosciences, Inc. Common Stock's stock price?

MBX Biosciences, Inc. Common Stock (MBX) trades at $30.22.

Is MBX Biosciences, Inc. Common Stock overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of MBX Biosciences, Inc. Common Stock (MBX)?

The analyst target price is $62.55, representing +107.0% upside from the current price of $30.22.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

13.14 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-27.80%

Beta—

50D MA$31.71

200D MA$24.98

Shares out0.05B

Float0.03B

Short ratio—

Avg volume0.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MBX vs LLY →MBX vs JNJ →MBX vs ABBV →Stock screener →